2026.08.03
On July 30, 2026, Nanjing Impact Therapeutics (together with its affiliates, collectively referred to as Impact Therapeutics), announced an exclusive licensing agreement with Pharmanovia for Senaparib in Europe, the Middle East and North Africa, Australia, and New Zealand. Impact Therapeutics is an innovative drug research and development company specializing in synthetic lethality in oncology, while Pharmanovia is a global pharmaceutical company that collaborates with innovative biotech and large pharmaceutical companies to provide patients with specialty medicines.
The agreement grants Pharmanovia exclusive rights to manufacture, develop and commercialize Senaparib in 66 countries for the maintenance monotherapy treatment of advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer. These countries include all 27 EU member states as well as the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and countries in the Middle East and North Africa.
Impact Therapeutics is expected to receive up to 423.5 million euros in upfront payments, near-term registration milestone payments, and commercialization milestone payments upon reaching various sales goals, as well as tiered royalties based on net sales of the product, reaching up to the mid-twenties.
JunHe was entrusted by Impact Therapeutics to review, amend and negotiate the agreement for this project. JunHe’s team earned the trust and recognition of the client with its consistently efficient, rigorous work style and meticulous, dedicated service attitude.
The project was led by partner ZHAO, Hao (Gerry), with significant support from WEI, Yingling in the field of antitrust.
